Iovance Biotherapeutics (IOVA) Enterprise Value (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Enterprise Value for 16 consecutive years, with -$313.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 12.86% year-over-year to -$313.4 million; the TTM figure through Mar 2026 stood at -$313.4 million (up 12.86% YoY), while the FY2025 annual figure was -$297.0 million, up 8.28% from the prior year.
• Enterprise Value declined to -$313.4 million in Q1 2026 per IOVA's latest filing, from -$297.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$164.2 million in Q3 2024 and bottomed at -$626.3 million in Q1 2023.
• Historically, Enterprise Value has averaged -$347.2 million across 5 years, with a median of -$323.8 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 54.56% — and 2025, when it plunged 83.21%.
• Iovance Biotherapeutics' Enterprise Value stood at -$471.8 million in 2022, then jumped by 40.69% to -$279.9 million in 2023, then declined by 15.69% to -$323.8 million in 2024, then climbed by 8.28% to -$297.0 million in 2025, then declined by 5.54% to -$313.4 million in 2026.
• Business Quant data shows IOVA's Enterprise Value at -$313.4 million in Q1 2026, -$297.0 million in Q4 2025, and -$300.8 million in Q3 2025.